EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Validation of the Up7-ALBI Score for Prognostication in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab

Chien-Hung Lu, Wei-Yu Kao, Yao-Yu Hsieh, Chia-Chi Wang, Ming-Shun Wu, Chih-Horng Wu, Tsung-Hao Liu iD, Wei-Yi Ting, Shan-Chia Wu, Kai-I Chuang, Chien-Wei Su, Chun-Chao Chang und 1 weitere

Journal of Hepatocellular Carcinoma · 2026-10 · Volume 13 · 1-12

DOI: 10.2147/jhc.s638385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-10. Verfasst von Chien-Hung Lu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

immunotherapyliver canceroverall survivalprognosisprogression-free survival

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
  • Division of Integrative Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • TMU Research Center for Digestive Medicine, Taipei Medical University, Taipei, Taiwan.
  • Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, Taipei, Taiwan.
  • Division of Hematology and Oncology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.

ORCID-Profile: Tsung-Hao Liu, San-Chi Chen

Zitieren

APA

Lu, C. H., Kao, W. Y., Hsieh, Y. Y., Wang, C. C., Wu, M. S., Wu, C. H., Liu, T. H., Ting, W. Y., Wu, S. C., Chuang, K. I., Su, C. W., Chang, C. C., & Chen, S. C. (2026). Validation of the Up7-ALBI Score for Prognostication in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab. Journal of Hepatocellular Carcinoma, Volume 13, 1-12. https://doi.org/10.2147/jhc.s638385

Vancouver

Lu CH, Kao WY, Hsieh YY, Wang CC, Wu MS, Wu CH, et al. Validation of the Up7-ALBI Score for Prognostication in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-12. doi:10.2147/jhc.s638385

BibTeX
@article{Lu2026,
  author = {Lu, Chien-Hung and Kao, Wei-Yu and Hsieh, Yao-Yu and Wang, Chia-Chi and Wu, Ming-Shun and Wu, Chih-Horng and Liu, Tsung-Hao and Ting, Wei-Yi and Wu, Shan-Chia and Chuang, Kai-I and Su, Chien-Wei and Chang, Chun-Chao and Chen, San-Chi},
  title = {Validation of the Up7-ALBI Score for Prognostication in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab},
  journal = {Journal of Hepatocellular Carcinoma},
  year = {2026},
  volume = {Volume 13},
  pages = {1--12},
  doi = {10.2147/jhc.s638385}
}
Kostenlos starten →